南财智讯1月29日电，古汉医药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-5500万元—-4500万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-6500万 元—-5500万元。报告期内，归属于上市公司股东净利润亏损的主要原因：（一）受行业政策等因素影 响，加之上游部分原材料采购成本上涨，致使整体毛利略有下降。（二）依据《会计监管风险提示第8 号——商誉减值》相关规定，综合考虑行业发展趋势、市场环境变化及标的资产实际经营状况，对收购 广东先通股权所形成的商誉及相关资产组进行减值测试并计提相应减值准备。（三）根据企业会计准则 及相关会计政策规定，结合公司的实际经营情况，计提应收款项信用减值准备。 ...

古汉医药公告，预计2025年度净利润亏损4500万元至5500万元。受行业政策等因素影响，加之上游部分 原材料采购成本上涨，致使整体毛利略有下降。 ...

证券代码：000590 证券简称：古汉医药 公告编号：2026-003 古汉医药集团股份公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 一、本期业绩预计情况 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | -5,500 | ～ | -4,500 | -12,547.15 | | 扣除非经常性损益后的净利润 | -6,500 | ～ | -5,500 | -16,981.70 | | 基本每股收益（元/股） | -0.2297 | ～ | -0.1879 | -0.5240 | | 营业收入（如适用） | 32,000 | ～ | 34,500 | 34,320.81 | | 扣除后营业收入（如适用） | 30,500 | ～ | 32,000 | 33,767.68 | ...

证券日报网讯1月27日，古汉医药（000590）在互动平台回答投资者提问时表示，根据《深圳证券交易 所股票上市规则》的相关规定，若公司满足业绩预告相应条件，公司将在会计年度结束后的一个月内对 年度经营情况进行业绩预告，并确定披露相关事宜。 ...

● 本报记者 昝秀丽 证监会今年开出的"1号罚单"直指操纵市场行为，对自然人余韩操纵"博士眼镜"股价罚没逾10亿元；浙 江证监局对向日葵重组预案涉嫌误导性陈述立案调查；深交所对因涉嫌财务数据存在虚假记载被证监会 立案的*ST立方、*ST长药进行重点监控……近日，一系列监管案例密集公布，彰显出监管部门对市场 违法行为"零容忍"的坚决态度，传递出强化交易监管、维护市场公平、防止大起大落的明确信号。 从行政处罚到刑事追责，从精准打击到平台共治，监管部门正构建起一张多维度、立体化的监管网络， 着力打造"不敢违、不能违、不想违"的长效治理格局，以监管效能的提升推动市场生态持续净化。 严打异常炒作 维护市场稳定运行 无独有偶，同样面临退市风险的*ST长药连续多个交易日涨停。然而，炒作热潮难掩退市定局，*ST长 药1月23日晚间发布的公告称，公司当日收到证监会行政处罚决定书，深交所同步下发事先告知书，明 确拟终止其股票上市。 针对此类乱象，相关部门反应迅速、出手精准。深交所于1月23日明确表态，对因涉嫌财务数据存在虚 假记载被证监会立案的*ST立方、*ST长药进行重点监控。 浙江裕丰律师事务所律师厉健分析，异常波动背后常伴 ...

Core Viewpoint - A significant number of companies in the A-share market have reported substantial losses, leading to a collective loss of 500 billion yuan, indicating a severe financial crisis within the industry [1][20]. Group 1: Company Losses - 65 companies disclosed their financial troubles, with major players like Red Star Macalline, Jindi Group, and Jianfa Holdings reporting massive losses of 225 billion, 135 billion, and 100 billion yuan respectively [4][10]. - The losses from these three companies alone could have been sufficient to acquire an entire medium-sized sector, highlighting the scale of the financial damage [5]. - The losses are attributed to asset impairment and the devaluation of previously overvalued properties, leading to a collapse in investor confidence [8][20]. Group 2: Market Reactions - The market appears to be in a state of denial, with indices showing resilience while individual stocks suffer severe declines, indicating a disconnect between market perception and reality [3][10]. - The financial reports have led to a significant drop in stock prices, undermining the belief in "core assets" and revealing the fragility of the market [10][20]. Group 3: Financial Strategies - The phenomenon of "financial big washing" is observed, where companies are using accounting flexibility to report massive losses in one go, potentially to reset their financial baselines for future reporting [17][20]. - This strategy allows companies to clear hidden liabilities and prepare for a potential recovery, but it also risks eroding investor trust [20][21]. Group 4: Regulatory Environment - The current regulatory environment, including the new registration system, has increased the pressure on companies to maintain transparency and avoid continuous losses, which could lead to delisting [21][22]. - Companies are advised to focus on fundamental performance rather than speculative trading, as the market is becoming increasingly unforgiving towards those with deteriorating fundamentals [21].

本报记者 吴晓璐 当日，已经连续3日涨停的*ST立方打开涨停板，收盘依旧上涨13.91%，4个交易日涨幅接近100%。类似情况也出现在同样 面临重大违法强制退市风险的长江医药控股股份有限公司（以下简称"*ST长药"）上。截至1月23日，该股连续4个交易日涨 停，累计涨幅达109.09%。1月23日晚间，*ST长药收到证监会《行政处罚决定书》，深交所也对公司下发《事先告知书》，决 定终止公司股票上市交易，其退市命运基本确定。 1月23日，安徽证监局发布关于立方数科股份有限公司（以下简称"*ST立方"）相关情况的通报，提醒*ST立方存在重大违 法强制退市风险，请广大投资者以公司正式公告内容为准，理性投资，避免被不实信息误导，造成损失。 华东政法大学国际金融法律学院教授郑彧对《证券日报》记者表示，在我国的证券监管体系下，所有涉及上市公司重大信 息均需要通过法定渠道披露，任何其他主体的公开性信息发布都可能构成违法，严重者甚至可能涉及操纵市场犯罪。 上海明伦律师事务所律师王智斌对《证券日报》记者表示，与退市有关的信息均属于重大信息，按照《上市公司信息披露 管理办法》第八条的规定，与公司有关的重大信息必须通过信披渠道发布 ...

Group 1 - The Shanghai Stock Exchange (SSE) reported that from January 19 to 23, it took self-regulatory measures against 152 cases of abnormal trading behaviors, including price manipulation and false declarations [1] - The SSE focused on monitoring stocks with significant volatility, such as *ST Zhengping, *ST Yazhen, Guosheng Technology, Tiangpu Co., and Shangwei New Materials, and conducted special investigations on 20 major corporate events, reporting 3 suspected illegal cases to the China Securities Regulatory Commission (CSRC) [1] - The Shenzhen Stock Exchange (SZSE) took self-regulatory measures against 326 cases of abnormal trading behaviors during the same period, involving price manipulation and false declarations [1] Group 2 - The SZSE specifically monitored *ST Lifang and *ST Changyao, which are under investigation by the CSRC for suspected false financial reporting, and conducted investigations on 6 major corporate events, reporting 1 suspected illegal case to the CSRC [1] - The Beijing Stock Exchange (BSE) continued to monitor the delisting risk warning stock "*ST Yunchuang" and took self-regulatory measures against 17 cases of abnormal trading behaviors, including price manipulation and false declarations [1] - The BSE also conducted a special investigation on 1 major corporate event during this period [1]

本报讯（记者 梁圣）近日，国药集团同济堂（贵州）制药有限公司、贵州省天然产物研究中心联合中 国食品发酵工业研究院主导制定的国际标准《Cili Juice—Specification and test methods刺梨汁—规格和 测试方法》（ISO/WD26093）成功立项。 该项研究工作于2024年9月开始筹划，2025年7月正式向国际标准化组织食品委员会果蔬及其制品分委会 （ISO/TC34/SC3）提出并开启了该标准的立项工作。历经3个月的投票周期，国际标准提案顺利通过立 项。其中，俄罗斯、塞尔维亚、斯里兰卡、土耳其等5个国家指派专家参与项目制定工作，与中国团队 共同组成了标准起草工作组。项目制定周期为36个月，预计于2028年正式发布。 该项国际标准的成功立项，不仅是对果蔬及其制品领域国际标准体系的重要完善，更提升了我国在该领 域规则制定中的话语权与国际影响力。该标准的制定不仅有助于规范刺梨行业生产流程，提升产品质量 与安全水平，推动技术创新和产业升级，还将有效消除国际贸易壁垒，提升全球市场认可度和竞争力， 促进国际交流与合作。 转自：贵州日报 贵州是全国刺梨产业的发源地、引领地，刺梨种植面积、加工产 ...

Core Viewpoint - Guhanshan Pharmaceutical is leveraging its partnership with Hengchang Pharmaceutical Group to expand its market reach and enhance product competitiveness, particularly focusing on its flagship product, Guhanshan Health Essence [1][2]. Group 1: Company Overview - Guhanshan Pharmaceutical, established in 1996, is the first pharmaceutical company listed in Hunan Province, with its core product, Guhanshan Health Essence, based on a 2200-year-old ancient health formula [1]. - The company has achieved remarkable sales performance, with Guhanshan Health Essence reportedly selling approximately 4 units per second in the Hunan OTC retail market [1]. Group 2: Strategic Developments - The company has undergone a control change in 2025, with Jiang Jin becoming the new actual controller, and has formed a strategic partnership with Hengchang Pharmaceutical Group, leading to a rebranding from "Qidi Pharmaceutical" to "Guhanshan Pharmaceutical" [1]. - Guhanshan Pharmaceutical aims to optimize its existing product lines and production capacity, with plans to restore production for over 30 varieties this year, focusing on achieving positive cash flow [2]. Group 3: Market Expansion and Collaboration - Hengchang Pharmaceutical Group currently serves over 200,000 member pharmacies and clinics, generating nearly 4 billion yuan in annual sales, which positions it as a significant partner for Guhanshan Pharmaceutical [2]. - The collaboration is expected to enhance the operational capabilities of both companies, creating a "front store and back factory" ecosystem that supports the growth of small and medium-sized pharmacies [2]. Group 4: Future Growth Strategies - Guhanshan Pharmaceutical plans to build a product matrix centered around Guhanshan Health Essence, while also expanding into chemical drugs and health food sectors [3]. - The company is focusing on integrating cultural tourism with traditional Chinese medicine and promoting intelligent, flexible production methods [3].